Clinical Trials Browser

Phase 2 × Not yet recruiting × Idarubicin × Clear all

NCT06050941 2024-03-05

Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS

Phase 2 Not yet recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute